Recruitment unclearEUCTR 2009-018038-12
A 26-week, multi-center, open-label, flexible dose, long-term safety trial of asenapine in adolescent subjects with schizophrenia
This historical record does not confirm current site availability.
Historical research recordRomania
Understand this study
What is this study about?
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
Who could participate?
This study is for people with schizophrenia. Other eligibility criteria apply.
- Listed locations
- Romania
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
What to know before participating
A point to clarify
This is historical registry information. What is the current study status and protocol?
Things to check before joining
Study start dateNot clearly listed
- Recruitment status
- Recruitment unclear
- Enrollment listed in the registry
- 150
- Sponsor
- Schering-Plough Research Institute, a Division of Schering Corporation
- Sponsor type
- Research institute
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Romania
- Age range
- Not clearly listed
- Official registry ID
- EUCTR 2009-018038-12
- Official title
Show the full official title
A 26-week, multi-center, open-label, flexible dose, long-term safety trial of asenapine in adolescent subjects with schizophrenia
Recruitment & locations
Status unknownRomania
Registry details
Historical country statuses
- Outside EU/EEA — Not reported
- Romania — Completed
A listed location does not confirm current availability.
Questions about this study
Who is behind this study?
The study sponsor is Schering-Plough Research Institute, a Division of Schering Corporation, a research institute.
Who can participate?
This study is for people with schizophrenia. Other eligibility criteria apply.
Want to explore more studies?
Explore studiesRelated studies
A PHASE II/III, PROSPECTIVE, MULTI-CENTER, RANDOMIZED, 4-WEEK, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, DESIGNED TO DETERMINE THE SAFETY, TOLERABILITY, EEG EFFECTS AND EFFICACY OF ORAL DOSES OF 30 M...
A Randomized, Double-blind, Active Comparator-Controlled Study to Evaluate the Long-term Safety and Tolerability of SEP-363856 in Subjects with Schizophrenia